Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Twice-weekly vs once-weekly Krd in early relapsed refractory multiple myeloma

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 25.09.19
Views: 744
Rating:

Prof Xavier Leleu - CHU la Miletrie, Poitiers, France

Prof Xavier Leleu speaks to ecancer at the 2019 International Myeloma Workshop meeting in Boston about the long-term exposure data on KRd
weekly given until progression.

Prof Leleu explains that one of the disadvantages of carfilzomib is that it is administered at the twice a week which is difficult for patients.

He reveals that the ARROW study is comparing the two courses and preliminary data from smaller studies suggests that the activity is the same with once-weekly proving much safer.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

Biosimilar Medicines Core Principles and Communication


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation